Clofibrate reduces serum lipid levels, interferes with blood clotting, and may possibly alter aqueous humour dynamics. It has been used in the treatment of hard retinal exudates, retinal vascular occlusion, lipidosis oculi, and certain types of glaucoma.
and 35 observed as controls for periods in excess of 12 months, with results which not only largely confirm the earlier findings (Table I) but also shed further light on the clinical effects of clofibrate. Thus, the institution of therapy in thirteen patients who developed macular exudates after being observed as controls for periods in excess of one year gave a mini-trial with built-in controls. Three of these patients subsequently showed a clearance of exudates in both eyes and four in one eye, in five the deterioration was halted in both eyes, and in only one has there been a continued increase in hard exudates. This provides more definite evidence than was hitherto available that the progressive increase in hard exudates in most cases of exudative diabetic retinopathy can be arrested and reversed by clofibrate therapy. Again, clofibrate therapy has been stopped in fourteen patients because of complete clearance of exudates from the macular regions. The duration of therapy required for this clearance varied from 24 to 56 months. These patients have since been followed up for periods ranging from 6 to 37 months. Four The haemorrhagic aspect of the retinopathy is completely unaffected for better or worse by clofibrate therapy (Table II, opposite) . This confirms the conclusions reached in the earlier studies.
Whilst these earlier studies have shown a slight but non-significant improvement in visual acuity with clofibrate therapy, our 5-year results indicate that this improvement may be greater than previously recognized. Cullen (I967) obtained a significant fall in intra-ocular pressure in seven eyes of ten patients with chronic simple or secondary glaucoma with high tonometry readings.
The mechanism of this action of clofibrate may be due to its effect on circulating steroid levels, perhaps by altering the mucopolysaccharide in the anterior chamber angle, as postulated by Armaly (I963) . It may also be due to the effect on thyroxin levels.
McLenachan and Davies (I965) found a history of thyroid disease in 45 out of a hundred patients with open-angle glaucoma and a history of previous illness. It is not clear from their paper whether hypo-or hyper-thyroidism predominated at the time of diagnosis of glaucoma, but they postulate a relationship between thyroid function and the anterior chamber angle mucopolysaccharides.
The hypolipaemic effect of clofibrate is unlikely to be responsible as no definite relationship has ever been shown between serum lipids and chronic glaucoma.
Side-effects
The drug is well tolerated and safe. Oliver (I967) discussed the finding of an average weight increase in a group of 51 patients with ischaemic heart disease who were on clofibrate; this was the only side-effect he encountered. There is no increase in plasma volume or total body water with the drug (Macmillan, Oliver, Simpson, and Tothill, I965) and it was suggested that the weight increase was due to an increase in adipose tissue. Oliver postulated an increased calorie intake as the cause. No such weight increase has occurred in our patients on clofibrate therapy for diabetic retinopathy; our patients were all on diets, which lends support to Oliver's theory. Clofibrate has a slight laxative effect due to its oily nature but this is not troublesome. One diabetic patient with a long history of drug allergies developed generalized urticaria 24 hours after starting clofibrate; she promptly stopped the drug and her rash cleared. One 40-year-old male with severe diabetic neuropathy developed impotence, which he blamed on clofibrate; however, the impotence cleared up and has not returned despite a second course of clofibrate therapy.
Thus the only side-effect which might genuinely be blamed on clofibrate has been the one case of urticaria in a patient with a history of allergy, and even this has not been proven. Clofibrate causes some lowering of intra-ocular pressure in cases of chronic simple glaucoma with high tonometry readings and possibly also in other types of glaucoma. It cannot be recommended in the treatment of glaucoma in our present stage of knowledge, but opens the gate to a new field of research on this subject.
The drug is safe, well tolerated, and easy to take.
